HLA-E Antibody / HLA class I histocompatibility antigen E, 100ug

HLA-E antibody targets HLA class I histocompatibility antigen E, a non-classical major histocompatibility complex class I molecule encoded by the HLA-E gene. HLA-E is primarily localized to the cell surface and functions as an important immune regulatory molecule rather than a classical antigen-presenting HLA protein. Unlike highly polymorphic classical HLA class I molecules such as HLA-A, HLA-B, and HLA-C, HLA-E shows limited polymorphism and serves specialized roles in innate and adaptive immune surveillance.<br><br>HLA class I histocompatibility antigen E is best known for its interaction with inhibitory and activating receptors on natural killer (NK) cells, particularly the CD94/NKG2 receptor family. By presenting a restricted set of leader sequence-derived peptides from other HLA class I molecules, HLA-E delivers inhibitory signals through CD94/NKG2A, thereby protecting healthy cells from NK cell-mediated cytotoxicity. For this reason, HLA-E is often described as a non-classical MHC class I molecule and a key ligand involved in immune tolerance and self-recognition. An HLA-E antibody is therefore widely used in studies of NK cell biology and immune checkpoint regulation.<br><br>Beyond NK cell regulation, HLA-E also participates in antigen presentation to subsets of CD8-positive T cells. Certain HLA-E-restricted T cells recognize pathogen-derived peptides, linking HLA-E to antimicrobial and antiviral immune responses. Expression of HLA-E can be upregulated by inflammatory cytokines and cellular stress, further emphasizing its role at the intersection of innate and adaptive immunity. Use of an HLA-E antibody enables investigation of these context-dependent expression patterns in both normal and disease-associated tissues.<br><br>HLA-E expression has gained particular relevance in cancer immunology. Many tumors upregulate HLA class I histocompatibility antigen E as a mechanism of immune evasion, exploiting its inhibitory signaling to suppress NK cell activity. Elevated HLA-E expression has been reported in multiple solid tumors and hematologic malignancies, where it may contribute to reduced immune-mediated tumor clearance. An HLA-E antibody is therefore an important research tool for studying tumor immune escape mechanisms and for evaluating immune checkpoint pathways beyond classical PD-1 or CTLA-4 signaling.<br><br>At the structural level, HLA-E associates with beta-2 microglobulin and binds short peptides derived predominantly from signal sequences of other HLA class I proteins. This restricted peptide repertoire distinguishes HLA-E from classical MHC class I molecules and underlies its specialized immune regulatory function. Because of its defined biology and clinical relevance, HLA-E is frequently examined in studies of transplantation, viral infection, inflammatory disease, and cancer immunotherapy.<br><br>Clone HLAE/9467 is designed to recognize HLA class I histocompatibility antigen E and supports detection of HLA-E expression in research applications. NSJ Bioreagents offers this HLA-E antibody to support investigations into NK cell regulation, immune tolerance, tumor immunology, and non-classical MHC class I biology.

Specifications